(Q40413455)

20 September 2017

title

Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation (English)

1 reference

20 September 2017

1 reference

Liang Guo

1

1 reference

20 September 2017

Heather Guthrie

series ordinal

2

1 reference

20 September 2017

publication date

1 July 2005

1 reference

Journal of Pharmacological and Toxicological Methods

20 September 2017

published in

1 reference

20 September 2017

volume

52

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

123-135

1 reference

Trends in ion channel drug discovery: advances in screening technologies

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

The long QT syndromes: genetic basis and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Calculation of hydrophobic constant (log P) from .pi. and f constants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Drug-induced prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Automated high-throughput patch-clamp techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Functional and pharmacological properties of canine ERG potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Patch clamping by numbers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Modulation of human ether-à-go-go-related K+ (HERG) channel inactivation by Cs+ and K+.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.04.002

10.1016/J.VASCN.2005.04.002

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference